Rybelsus

Novo Nordisk
Marketing

Rybelsus brand retired in US as ‘Ozempic pill’ takes the stage

The semaglutide franchise is changing up its branding as Novo Nordisk is retiring the Rybelsus name in favor of its better-known brand.
Novo Nordisk

Novo eyes adolescent diabetes approval for oral semaglutide

Apr 23, 2026 11:03am
Novo Nordisk

Novo reports 2 trial failures for GLP-1 in Alzheimer's disease

Nov 24, 2025 11:41am
Rybelsus

Novo's Rybelsus gains FDA expansion to reduce risk of MACE

Oct 21, 2025 10:45am
Novo Nordisk

Novo Nordisk applies for FDA approval of semaglutide obesity pill

Apr 22, 2025 8:50am
Rybelsus

Novo's oral GLP-1 Rybelsus cuts heart disease risks

Mar 31, 2025 11:30am